Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Pediatr ; 166(6): 1358-63.e1-3, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25771388

ABSTRACT

OBJECTIVE: To evaluate the efficacy and safety of omega-3 fatty acid supplementation in children with nonalcoholic fatty liver disease (NAFLD). STUDY DESIGN: Overweight/obese children with NAFLD (n = 76; median age, 13 years; IQR, 11.1-15.2 years) were eligible to participate in the study. The diagnosis of NAFLD was based on elevated alanine aminotransferase (ALT) to ≥ 30% of the upper limit of normal (ULN) and liver hyperechogenicity on ultrasound. Patients were randomized to receive omega-3 fatty acids (docosahexaenoic acid and eicosapentaenoic acid, 450-1300 mg/day) or placebo (omega-6 sunflower oil). The primary outcome was the number of patients who demonstrated decreased ALT activity by ≥ 0.3 times the ULN. Secondary outcomes included alterations in liver function tests, liver hyperechogenicity, insulin resistance, and other metabolic markers after 6 months of intervention. RESULTS: Out of 76 enrolled patients, 64 completed the trial and were analyzed. After 6 months, we found no significant differences between the omega-3 and placebo groups in the number of patients with decreased ALT by ≥ 0.3 times the ULN (24 vs 23) or in median (IQR) ALT activity (48.5 [31-62] U/L vs 39 [27-55] U/L), liver hyperechogenicity, insulin resistance, or serum lipid levels. However, patients in the omega-3 group had lower levels of aspartate aminotransferase (28 [25-36] U/L vs 39 [27-55] U/L; P = .04) and gamma-glutamyl transpeptidase (26 [17.5-36.5] U/L vs 35 [22-52] U/L; P = .04), and significantly higher levels of adiponectin. CONCLUSION: Omega-3 fatty acid supplementation did not increase the number of patients with decreased ALT levels and it did not affect liver steatosis on ultrasound, but it improved aspartate aminotransferase and gamma-glutamyl transpeptidase levels in children with NAFLD compared with placebo. TRIAL REGISTRATION: Registered with ClinicalTrials.gov: NCT01547910.


Subject(s)
Fatty Acids, Omega-3/therapeutic use , Non-alcoholic Fatty Liver Disease/drug therapy , Adolescent , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Child , Dietary Supplements , Double-Blind Method , Female , Humans , Male , Non-alcoholic Fatty Liver Disease/blood , gamma-Glutamyltransferase/blood
2.
BMC Pediatr ; 13: 85, 2013 May 23.
Article in English | MEDLINE | ID: mdl-23702094

ABSTRACT

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome since obesity and insulin resistance are the main pathogenic contributors for both conditions. NAFLD carries increased risk of atherosclerosis and cardiovascular diseases. There is an urgent need to find effective and safe therapy for children and adults with NAFLD. Data from research and clinical studies suggest that omega-3 fatty acids may be beneficial in metabolic syndrome-related conditions and can reduce the risk of cardiovascular disease. METHODS/DESIGN: We are conducting a randomized, multicenter, double-blind, placebo-controlled trial of treatment with omega-3 fatty acids in children with NAFLD. Patients are randomized to receive either omega-3 fatty acids containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) or placebo for 24 weeks. The dose of omega-3 (DHA+ EPA) ranges from 450 to 1300 mg daily. Low calorie diet and increased physical activity are advised and monitored using validated questionnaires. The primary outcome of the trial is the number of patients who decreased ALT activity by ≥ 0,3 of upper limit of normal. The main secondary outcomes are improvement in the laboratory liver tests, liver steatosis on ultrasound, markers of insulin resistance and difference in fat/lean body mass composition after 6 months of intervention. DISCUSSION: Potential efficacy of omega-3 fatty acids in the treatment of NAFLD will provide needed rationale for use of this safe diet supplement together with weight reduction therapy in the growing population of children with NAFLD. TRIAL REGISTRATION: NCT01547910.


Subject(s)
Dietary Supplements , Docosahexaenoic Acids/therapeutic use , Eicosapentaenoic Acid/therapeutic use , Fatty Liver/diet therapy , Adolescent , Child , Clinical Protocols , Diet Records , Double-Blind Method , Follow-Up Studies , Humans , Non-alcoholic Fatty Liver Disease , Research Design , Treatment Outcome , Young Adult
3.
Hypertension ; 54(6): 1234-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19841285

ABSTRACT

It is hypothesized that primary hypertension (PH) is a disorder with origins in childhood linked to, at least in part, aberrations of growth and maturation processes. To evaluate the possible relation between the rate of biological maturity and development of PH, bone age (BA) assessments on the basis of dual x-ray absorptiometry-derived hand scans were performed in 54 newly diagnosed children and adolescents with PH and 54 healthy controls matched for body mass index (BMI), age and sex. Chronological age (CA), body height (in centimeters), body weight (in kilograms), BMI (in kilograms per meter squared), and blood pressure were assessed. Healthy controls had a mean BA of 14.7+/-2.3 years that was not significantly different from their mean CA of 14.2+/-2.1 years. In the PH group, the BA of 16.0+/-2.0 years was higher by 1.9+/-0.9 years compared with their CA of 14.1+/-2.0 years (P<0.0001). The magnitude of acceleration of skeletal maturation (BA-CA) and its prevalence (88.9%) were significantly higher in PH compared with BMI-matched controls (37.0%; chi(2)=31.4; P<0.0001). BA-CA values of PH patients were higher by 1.24 years in normal weight (P<0.0001), 1.80 years in overweight (P<0.01), and 1.40 years in obese (P<0.0001) subgroups of BMI z score-matched controls. Stepwise regression revealed that predictors of blood pressure status from normotension through prehypertension stages 1 and 2 of hypertension were BA-CA (beta=0.530; P<0.0.001), height (beta=-0.379; P<0.01), and CA (beta=0.298; P<0.05; R(2)=0.43). In conclusion, irrespective of BMI, advanced biological maturation should be considered as an independent marker for the development of hypertension.


Subject(s)
Bone Development , Bone Diseases/epidemiology , Growth Disorders/diagnostic imaging , Growth Disorders/epidemiology , Hypertension/epidemiology , Absorptiometry, Photon , Adolescent , Blood Pressure , Body Mass Index , Body Weight , Child , Female , Humans , Male , Obesity/epidemiology , Predictive Value of Tests , Prevalence
4.
Rocz Panstw Zakl Hig ; 58(1): 129-37, 2007.
Article in English | MEDLINE | ID: mdl-17711101

ABSTRACT

The main criteria of the metabolic syndrome are obesity, insulin resistance and disturbed lipid metabolism. The same disturbances are regarded to be involved into the pathomechanism of nonalcoholic fatty liver disease which is shown by epidemiological studies and animal models. Thus NAFLD can be regarded a specific feature of the metabolic syndrome and it should be looked for in high risk populations.


Subject(s)
Fatty Liver/etiology , Fatty Liver/physiopathology , Insulin Resistance , Lipid Metabolism Disorders/complications , Metabolic Syndrome/complications , Metabolic Syndrome/physiopathology , Animals , Body Mass Index , Diet, Diabetic/standards , Diet, Fat-Restricted/standards , Epidemiologic Studies , Fatty Liver/diet therapy , Humans , Hyperinsulinism/complications , Hyperinsulinism/physiopathology , Hypoglycemic Agents/therapeutic use , Lipid Metabolism Disorders/physiopathology , Obesity/complications , Obesity/physiopathology , Risk Factors , Syndrome , Weight Loss
SELECTION OF CITATIONS
SEARCH DETAIL
...